Literature DB >> 17275782

Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site.

Daisuke Yamamoto1, Shinji Takai, Mizuo Miyazaki.   

Abstract

To characterize the inhibitory specificity of angiotensin converting enzyme (ACE) inhibitors for matrix metalloproteinase 9 (MMP-9) activity, molecular modeling of these complex was performed referring the recent X-ray structure analyses using lisinopril as an ACE inhibitor. Two interaction modes differing in the orientation of the inhibitor on the active site were identified. Lisinopril was effectively stabilized by specific hydrogen bonds and hydrophobic interactions in the active site of MMP-9, and its hydrophobic group appeared to interact preferentially with the S1 site compared with the S1' site. These findings showed that ACE inhibitors could become important seeds for cardiovascular protection and the development of MMP inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275782     DOI: 10.1016/j.bbrc.2007.01.088

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients.

Authors:  Kana Wakabayashi; Takeshi Tsujino; Yoshiro Naito; Akira Ezumi; Masaaki Lee-Kawabata; Shinji Nakao; Akiko Goda; Yasushi Sakata; Kazuhiro Yamamoto; Takashi Daimon; Tohru Masuyama
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

2.  Influence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets.

Authors:  Edina Vranić; Alija Uzunović
Journal:  Bosn J Basic Med Sci       Date:  2007-11       Impact factor: 3.363

3.  ACE inhibitors to block MMP-9 activity: new functions for old inhibitors.

Authors:  Yufang Jin; Hai-Chao Han; Merry L Lindsey
Journal:  J Mol Cell Cardiol       Date:  2007-09-12       Impact factor: 5.000

Review 4.  The impact of aging on cardiac extracellular matrix.

Authors:  Cesar A Meschiari; Osasere Kelvin Ero; Haihui Pan; Toren Finkel; Merry L Lindsey
Journal:  Geroscience       Date:  2017-01-17       Impact factor: 7.713

Review 5.  Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.

Authors:  Kristine Y DeLeon-Pennell; Cesar A Meschiari; Mira Jung; Merry L Lindsey
Journal:  Prog Mol Biol Transl Sci       Date:  2017-03-18       Impact factor: 3.622

Review 6.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

7.  Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension.

Authors:  Rikki M Tanner; Amy I Lynch; Victoria H Brophy; John H Eckfeldt; Barry R Davis; Charles E Ford; Eric Boerwinkle; Donna K Arnett
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

8.  Isolation, purification and molecular mechanism of a peanut protein-derived ACE-inhibitory peptide.

Authors:  Aimin Shi; Hongzhi Liu; Li Liu; Hui Hu; Qiang Wang; Benu Adhikari
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

9.  A role of matrix metalloproteinase-8 in atherosclerosis.

Authors:  Ross C Laxton; Yanhua Hu; Johan Duchene; Feng Zhang; Zhongyi Zhang; Kit-Yi Leung; Qingzhong Xiao; Ramona S Scotland; Conrad P Hodgkinson; Katherine Smith; Johann Willeit; Carlos López-Otín; Iain A Simpson; Stefan Kiechl; Amrita Ahluwalia; Qingbo Xu; Shu Ye
Journal:  Circ Res       Date:  2009-09-10       Impact factor: 17.367

10.  Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury.

Authors:  Rugmani Padmanabhan Iyer; Mira Jung; Merry L Lindsey
Journal:  Metalloproteinases Med       Date:  2015-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.